miR-590-3p is a novel microRNA which suppresses osteosarcoma progression by targeting SOX9

Wan-Tao Wang1, Quan Qi1, Peng Zhao1

  • 1Department of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, 150081, PR China.

Insights

MicroRNA-590-3p (miR-590-3p) acts as an anti-cancer agent in osteosarcoma by inhibiting cell proliferation and metastasis. This study identifies SOX9 as a direct target, suggesting miR-590-3p and SOX9 as potential therapeutic targets for osteosarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Osteosarcoma is the most common primary bone cancer in children and adolescents.
  • MicroRNA-590 (miR-590) exhibits anti-tumor properties in various cancers, but its role in osteosarcoma is unclear.

Purpose of the Study:

  • To investigate the function of miR-590-3p in osteosarcoma.
  • To identify potential molecular targets of miR-590-3p in osteosarcoma.

Main Methods:

  • Quantitative analysis of miR-590-3p expression in osteosarcoma tissues and cell lines.
  • Cell viability, proliferation, invasion, and migration assays following miR-590-3p mimic transfection.
  • Western blot and dual-luciferase reporter assays to validate SOX9 as a direct target of miR-590-3p.

Main Results:

  • miR-590-3p expression was significantly downregulated in osteosarcoma.
  • Overexpression of miR-590-3p inhibited osteosarcoma cell viability, proliferation, invasion, and migration.
  • SOX9 was identified as a direct target of miR-590-3p and its expression was inversely correlated with miR-590-3p levels.
  • Restoration of SOX9 expression partially reversed the anti-tumor effects of miR-590-3p.

Conclusions:

  • miR-590-3p functions as a tumor suppressor in osteosarcoma by inhibiting cell proliferation and metastasis.
  • SOX9 is a key mediator of miR-590-3p's tumor-suppressive activity in osteosarcoma.
  • miR-590-3p and SOX9 represent potential therapeutic targets for osteosarcoma treatment.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
704
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
958